array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(13) "Pharming B.V."
["slug"]=>
string(20) "00474-nl-pharming-bv"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776"
["description"]=>
string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates."
["address_street"]=>
string(12) "Darwinweg 24"
["address_place"]=>
string(6) "Leiden"
["address_region"]=>
NULL
["founding_date"]=>
NULL
["website_domain"]=>
string(12) "pharming.com"
["website_url"]=>
string(24) "https://www.pharming.com"
["industry_codes"]=>
array(1) {
[0]=>
string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified"
}
["employee_count"]=>
NULL
["article_count"]=>
int(54)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(70) "Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price"
["snippet_en"]=>
string(122) "With a price-to-sales (or "P/S") ratio of 3.4x Pharming Group N.V. ( AMS:PHARM ) may be sending very bullish signals at..."
["url"]=>
string(153) "https://simplywall.st/stocks/nl/pharmaceuticals-biotech/ams-pharm/pharming-group-shares/news/revenues-working-against-pharming-group-nvs-amspharm-share-p"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/fe08ec05-c725-4afc-b7ee-d83ae48c4c6d"
["source"]=>
string(13) "simplywall.st"
["publication_date"]=>
string(10) "2024-02-14"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(15) "Market Movement"
[2]=>
string(24) "Stock Research & Ratings"
}
}
[1]=>
array(7) {
["title_en"]=>
string(84) "Pharming's share price rises by more than 9% thanks to higher than expected turnover"
["snippet_en"]=>
string(145) "Sales growth of 10% from medicine Ruconest is higher than the company expected. Investors react enthusiastically to the message and set course..."
["url"]=>
string(111) "https://fd.nl/financiele-markten/3693272/1502485/koers-pharming-stijgt-ruim-9-dankzij-hoger-dan-verwachte-omzet"
["image_url"]=>
NULL
["source"]=>
string(5) "fd.nl"
["publication_date"]=>
string(10) "2024-01-08"
["categories"]=>
array(5) {
[0]=>
string(15) "Market Movement"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(9) "Investors"
[3]=>
string(12) "Stock Market"
[4]=>
string(25) "Business Model Resilience"
}
}
[2]=>
array(7) {
["title_en"]=>
string(17) "TomThumb | IEX.nl"
["snippet_en"]=>
string(182) "IEX.nl is the investor platform in the Netherlands. Stay up to date with all relevant information about shares and other investment products. Investing - Price - Shares - Discussion."
["url"]=>
string(50) "https://www.iex.nl/Leden/1889443/KleinDuimpje.aspx"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/db424618-480e-4765-8a73-e7b49f525854"
["source"]=>
string(6) "iex.nl"
["publication_date"]=>
string(10) "2023-11-01"
["categories"]=>
array(6) {
[0]=>
string(12) "Board Change"
[1]=>
string(18) "Board Compensation"
[2]=>
string(20) "Corporate Governance"
[3]=>
string(12) "Stock Market"
[4]=>
string(18) "General Investment"
[5]=>
string(46) "Management of Legal and Regulatory Environment"
}
}
[3]=>
array(7) {
["title_en"]=>
string(75) "Pharming Group to report third quarter 2023 financial results on October 26"
["snippet_en"]=>
string(276) "Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023."
["url"]=>
string(81) "https://finance.yahoo.com/news/pharming-group-report-third-quarter-060000578.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/222fecfb-6b72-4556-9f3b-642d69c24b75"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2023-10-12"
["categories"]=>
array(5) {
[0]=>
string(31) "Financial Update/Profit Warning"
[1]=>
string(18) "Financial Distress"
[2]=>
string(24) "Quarterly/Annual Figures"
[3]=>
string(9) "Investors"
[4]=>
string(12) "Stock Market"
}
}
[4]=>
array(7) {
["title_en"]=>
string(52) "Attention to quarterly figures ING and SBM at Damrak"
["snippet_en"]=>
string(303) "SBM Offshore saw turnover fall by almost a quarter in the first quarter. CEO Bruno Chabas nevertheless spoke of good performance and maintained expectations for the entire year. The company will also pay out 10 percent more dividend over 2022. Pharming also came up with figures. The biotechnologist saw"
["url"]=>
string(84) "https://www.rd.nl/artikel/1019815-aandacht-voor-kwartaalcijfers-ing-en-sbm-op-damrak"
["image_url"]=>
NULL
["source"]=>
string(5) "rd.nl"
["publication_date"]=>
string(10) "2023-05-11"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(31) "Financial Update/Profit Warning"
}
}
[5]=>
array(7) {
["title_en"]=>
string(61) "Dutch biotech company receives US approval for drug, price up"
["snippet_en"]=>
string(136) "The share price of the Dutch biotech company Pharming shot up on Friday after it became known that the American medical regulator (FD..."
["url"]=>
string(118) "https://fd.nl/bedrijfsleven/3693272/1471682/nederlands-biotechbedrijf-krijgt-goedkeuring-vs-voor-medicijn-koers-omhoog"
["image_url"]=>
NULL
["source"]=>
string(5) "fd.nl"
["publication_date"]=>
string(10) "2023-03-24"
["categories"]=>
array(2) {
[0]=>
string(21) "Competitive Behaviour"
[1]=>
string(12) "Stock Market"
}
}
[6]=>
array(7) {
["title_en"]=>
string(35) "PHARMING in the rebound – 20Feb23"
["snippet_en"]=>
string(284) "'Daily Charts' Video Coaching with an explanation of the AEX and DAX daily chart every day after the close by technical analyst Nico Bakker to gain inspiration for the coming trading day. In addition, an extra Technical Tip of an interesting fund from a chart-technical point of view."
["url"]=>
string(69) "https://www.deaandeelhouder.nl/videos/pharming-in-de-rebound-20feb23/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/62d7c56f-90ca-4472-a6f7-a3bf72002426"
["source"]=>
string(18) "deaandeelhouder.nl"
["publication_date"]=>
string(10) "2023-02-20"
["categories"]=>
array(1) {
[0]=>
string(12) "Stock Market"
}
}
[7]=>
array(7) {
["title_en"]=>
string(72) "European stock markets rose slightly after a week of interest rate fears"
["snippet_en"]=>
string(184) "AMSTERDAM (ANP) - The European stock markets showed some recovery on Friday after the significant price losses earlier this week. The fear of higher interest rates, which the markets d"
["url"]=>
string(85) "https://www.zeelandnet.nl/nieuws/europese-beurzen-licht-omhoog-na-week-van-rentevrees"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/15fb18ac-5c61-4a8a-8f27-f1d9fce54f25"
["source"]=>
string(13) "zeelandnet.nl"
["publication_date"]=>
string(10) "2021-05-14"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(19) "Economic Conditions"
[2]=>
string(15) "Market Movement"
}
}
[8]=>
array(7) {
["title_en"]=>
string(27) "'AEX continues its decline'"
["snippet_en"]=>
string(252) "The stock exchange in Amsterdam will probably open with a loss on Thursday. The other stock exchanges in Europe also seem to start lower after the heavy price losses in Asia and on Wall Street. Investors are once again getting a good amount of business"
["url"]=>
string(73) "https://www.telegraaf.nl/financieel/2724384/aex-zet-neergang-stevig-voort"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/d684a4f8-4f2e-4f99-8b86-196d5b2e5a08"
["source"]=>
string(12) "telegraaf.nl"
["publication_date"]=>
string(10) "2018-10-24"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(15) "Market Movement"
[2]=>
string(9) "Investors"
}
}
}
["category_annotations"]=>
array(28) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(12)
}
[1]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(8)
}
[2]=>
array(2) {
["name"]=>
string(10) "Insolvency"
["count"]=>
int(4)
}
[3]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(4)
}
[4]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(3)
}
[5]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(3)
}
[6]=>
array(2) {
["name"]=>
string(9) "Investors"
["count"]=>
int(2)
}
[7]=>
array(2) {
["name"]=>
string(21) "Financial Performance"
["count"]=>
int(2)
}
[8]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(2)
}
[9]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(1)
}
[10]=>
array(2) {
["name"]=>
string(10) "Executives"
["count"]=>
int(1)
}
[11]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(1)
}
[12]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(1)
}
[13]=>
array(2) {
["name"]=>
string(24) "Government Interventions"
["count"]=>
int(1)
}
[14]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(1)
}
[15]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(1)
}
[16]=>
array(2) {
["name"]=>
string(21) "Shareholders Feedback"
["count"]=>
int(1)
}
[17]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(1)
}
[18]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(1)
}
[19]=>
array(2) {
["name"]=>
string(9) "Valuation"
["count"]=>
int(1)
}
[20]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(1)
}
[21]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(1)
}
[22]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(1)
}
[23]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(1)
}
[24]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(1)
}
[25]=>
array(2) {
["name"]=>
string(5) "Debts"
["count"]=>
int(1)
}
[26]=>
array(2) {
["name"]=>
string(19) "Economic Conditions"
["count"]=>
int(1)
}
[27]=>
array(2) {
["name"]=>
string(7) "Economy"
["count"]=>
int(1)
}
}
}
00474-nl-pharming-bv
Pharming B.V.
Location
Founded
Website
https://www.pharming.com
Articles
54 Articles
Category
Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified
Description
Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates.
IEX.nl is the investor platform in the Netherlands. Stay up to date with all relevant information about shares and other investment products. Investing - Price - Shares - Discussion.
Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.
SBM Offshore saw turnover fall by almost a quarter in the first quarter. CEO Bruno Chabas nevertheless spoke of good performance and maintained expectations for the entire year. The company will also pay out 10 percent more dividend over 2022. Pharming also came up with figures. The biotechnologist saw
'Daily Charts' Video Coaching with an explanation of the AEX and DAX daily chart every day after the close by technical analyst Nico Bakker to gain inspiration for the coming trading day. In addition, an extra Technical Tip of an interesting fund from a chart-technical point of view.
AMSTERDAM (ANP) - The European stock markets showed some recovery on Friday after the significant price losses earlier this week. The fear of higher interest rates, which the markets d
The stock exchange in Amsterdam will probably open with a loss on Thursday. The other stock exchanges in Europe also seem to start lower after the heavy price losses in Asia and on Wall Street. Investors are once again getting a good amount of business
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
